Talquetamab GPRC5D × CD3 bispecific monotherapy — SC (post step-up; QW or Q2W schedule)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-TALQUETAMAB |
|---|
| ID | REGIMEN-TALQUETAMAB-MONO-MM |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-01 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-MM-2025 |
Notes
Full-dose monotherapy phase of talquetamab (first-in-class GPRC5D × CD3 bispecific) — separated from step-up phase (REGIMEN-TALQUETAMAB-STEP-UP-DOSING-MM). MonumenTAL-1 (Chari 2022, NEJM): triple-class refractory MM after ≥3 prior lines — ORR ~74% (0.4 mg/kg QW), ~72% (0.8 mg/kg Q2W); mDOR ~9-13 mo. FDA approved 2023 for triple-class refractory MM. Orthogonal to BCMA — active in patients with prior BCMA exposure (~63% ORR after BCMA CAR-T / bispecific). Bibliographic record SRC-MONUMENTAL-1-CHARI-2022 is available; clinical claim linkage requires dual clinical sign-off.
Used By
No reverse references found in the YAML corpus.